|
1
|
Broaddus E, Topham A and Singh AD:
Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol.
93:21–23. 2009.
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
3
|
Giacinti C and Giordano A: RB and cell
cycle progression. Oncogene. 25:5220–5227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lillington DM, Kingston JE, Coen PG, et
al: Comparative genomic hybridization of 49 primary retinoblastoma
tumors identifies chromosomal regions associated with
histopathology, progression, and patient outcome. Genes Chromosomes
Cancer. 36:121–128. 2003. View Article : Google Scholar
|
|
5
|
Reis AH, Vargas FR and Lemos B: More
epigenetic hits than meets the eye: microRNAs and genes associated
with the tumorigenesis of retinoblastoma. Front Genet.
3:2842012.PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar
|
|
9
|
Jansson MD and Lund AH: MicroRNA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar
|
|
10
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bueno MJ and Malumbres M: MicroRNAs and
the cell cycle. Biochim Biophys Acta. 1812:592–601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kandalam MM, Beta M, Maheswari UK,
Swaminathan S and Krishnakumar S: Oncogenic microRNA 17–92 cluster
is regulated by epithelial cell adhesion molecule and could be a
potential therapeutic target in retinoblastoma. Mol Vis.
18:2279–2287. 2012.
|
|
13
|
Dalgard CL, Gonzalez M, deNiro JE and
O’Brien JM: Differential microRNA-34a expression and tumor
suppressor function in retinoblastoma cells. Invest Ophthalmol Vis
Sci. 50:4542–4551. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang J, Wang X, Wu G, Hou D and Hu Q:
MiR-365b-3p, down-regulated in retinoblastoma, regulates cell cycle
progression and apoptosis of human retinoblastoma cells by
targeting PAX6. FEBS Lett. 587:1779–1786. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YS and Dutta A: The tumor suppressor
microRNA let-7 represses the HMGA2 oncogene. Genes Dev.
21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Varambally S, Cao Q, Mani RS, et al:
Genomic loss of microRNA-101 leads to overexpression of histone
methyltransferase EZH2 in cancer. Science. 322:1695–1699. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chase A and Cross NC: Aberrations of EZH2
in cancer. Clin Cancer Res. 17:2613–2618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bracken AP, Pasini D, Capra M, Prosperini
E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway,
essential for proliferation and amplified in cancer. EMBO J.
22:5323–5335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Friedman JM, Liang G, Liu CC, et al: The
putative tumor suppressor microRNA-101 modulates the cancer
epigenome by repressing the polycomb group protein EZH2. Cancer
Res. 69:2623–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang HJ, Ruan HJ, He XJ, et al:
MicroRNA-101 is down-regulated in gastric cancer and involved in
cell migration and invasion. Eur J Cancer. 46:2295–2303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smits M, Nilsson J, Mir SE, et al: miR-101
is down-regulated in glioblastoma resulting in EZH2-induced
proliferation, migration, and angiogenesis. Oncotarget. 1:710–720.
2010.PubMed/NCBI
|
|
23
|
Zhang JG, Guo JF, Liu DL, Liu Q and Wang
JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small
cell lung cancer through directly targeting enhancer of zeste
homolog 2. J Thorac Oncol. 6:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao P, Deng Z, Wan M, et al: MicroRNA-101
negatively regulates Ezh2 and its expression is modulated by
androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer. 9:1082010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Zhang X, Jia LT, et al:
c-Myc-mediated epigenetic silencing of microRNA-101 contributes to
dysregulation of multiple pathways in hepatocellular carcinoma.
Hepatology. 59:1850–1863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu L, Beckebaum S, Iacob S, et al:
MicroRNA-101 inhibits human hepatocellular carcinoma progression
through EZH2 downregulation and increased cytostatic drug
sensitivity. J Hepatol. 60:590–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Luo C, Merz PR, Chen Y, et al: MiR-101
inhibits melanoma cell invasion and proliferation by targeting MITF
and EZH2. Cancer Lett. 341:240–247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakagawa S, Sakamoto Y, Okabe H, et al:
Epigenetic therapy with the histone methyltransferase EZH2
inhibitor 3-deazaneplanocin A inhibits the growth of
cholangiocarcinoma cells. Oncol Rep. 31:983–988. 2014.PubMed/NCBI
|
|
29
|
Yang YA and Yu J: EZH2, an epigenetic
driver of prostate cancer. Protein Cell. 4:331–341. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pushpavalli S, Ramaiah MJ, Srinivas CH, et
al: Effect of benzothiazole based conjugates in causing apoptosis
by regulating p53, PTEN and MAP kinase proteins affecting miR-195a
and miR-101–1. Cancer Cell Int. 11:362011.PubMed/NCBI
|
|
31
|
Ng SB, Yan J, Huang G, et al: Dysregulated
microRNAs affect pathways and targets of biologic relevance in
nasal-type natural killer/T-cell lymphoma. Blood. 118:4919–4929.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hiroki E, Akahira J, Suzuki F, et al:
Changes in microRNA expression levels correlate with
clinicopathological features and prognoses in endometrial serous
adenocarcinomas. Cancer Sci. 101:241–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Y, Guo X, Xiong L, et al:
MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes
favorable prognosis of human hepatocellular carcinoma. FEBS Lett.
586:4362–4370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yin J, Wang M, Jin C and Qi Q: miR-101
sensitizes A549 NSCLC cell line to CDDP by activating caspase
3-dependent apoptosis. Oncol Lett. 7:461–465. 2014.PubMed/NCBI
|
|
35
|
Xu Y, An Y, Wang Y, et al: miR-101
inhibits autophagy and enhances cisplatin-induced apoptosis in
hepatocellular carcinoma cells. Oncol Rep. 29:2019–2024.
2013.PubMed/NCBI
|
|
36
|
Lee KH, Chen YL, Yeh SD, et al:
MicroRNA-330 acts as tumor suppressor and induces apoptosis of
prostate cancer cells through E2F1-mediated suppression of Akt
phosphorylation. Oncogene. 28:3360–3370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Conkrite K, Sundby M, Mukai S, et al:
miR-17~92 cooperates with RB pathway mutations to promote
retinoblastoma. Genes Dev. 25:1734–1745. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kong W, Yang H, He L, et al: MicroRNA-155
is regulated by the transforming growth factor beta/Smad pathway
and contributes to epithelial cell plasticity by targeting RhoA.
Mol Cell Biol. 28:6773–6784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Volinia S, Calin GA, Liu CG, et al: A
microRNA expression signature of human solid tumors defines cancer
gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Su H, Yang JR, Xu T, et al: MicroRNA-101,
down-regulated in hepatocellular carcinoma, promotes apoptosis and
suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li S, Fu H, Wang Y, et al: MicroRNA-101
regulates expression of the v-fos FBJ murine osteosarcoma viral
oncogene homolog (FOS) oncogene in human hepatocellular carcinoma.
Hepatology. 49:1194–1202. 2009. View Article : Google Scholar : PubMed/NCBI
|
